Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07546669 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Zoster Vaccination in Glioblastoma Patients

Study acronym: STARGATE
StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
University Hospital, Essen
35 trials monitored
See 1 trial at risk
Glioma
1,251 trials monitored
See 88 trials at risk
Glioblastoma
710 trials monitored
See 52 trials at risk
In modern practice a trimodality treatment has emerged as standard of care for histologically confirmed glioblastoma. We hypothesize that the additional vaccination against herpes zoster, after surgical resection followed by irradiation therapy and chemotherapy of patients with glioblastoma will lead to a superior local control, overall and progression free survival. In an additional experimental setting based on patient preference the immunological effectiveness of the adoptive transfer of autologous polyclonal cytomegalovirus (CMV) specific T cells will be examined.
Trial Details
NCT Number NCT07546669
Lead Sponsor University Hospital, Essen
Collaborators: Karolinska Institutet, Leiden University Medical Center, Universitätsklinikum Hamburg-Eppendorf
Conditions
(from sponsor)		 Glioblastoma (GBM)
Related terms Glioblastoma
Enrollment 230 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov